Real-World Obesity Data Delivered to Your Platform
Real-World Obesity Data to Power Any
GLP-1 Strategic Application
FOR GLP-1 MARKET LEADERS:
Defend your position and forecast competitive threats with unmatched precision.
- Real-world Live Dashboard for US market share trends by patient segments and provider specialty
- Unmet medical need identification for pipeline development
- Comparative effectiveness positioning vs. competitors
- Discontinuation triggers and predictive modeling opportunities
FOR NEW MARKET ENTRANTS:
De-risk your launch strategy and accelerate market penetration by identifying unmet needs.
- Provider decision drivers for GLP-1 initiation, attempts, and changes
- Post-market surveillance capabilities for FDA requirements
- Health economics outcomes research for payer negotiations
- Launch sequence optimization for which patient segments to target first
FOR PIPELINE ASSETS:
Optimize clinical development and navigate regulatory pathways with robust real-world intelligence.
- Patient phenotyping for optimal clinical trial design
- Biomarker discovery opportunities in real-world populations
- Combination therapy optimization insights
FOR GLP-1 MARKET LEADERS:
Defend your position and forecast competitive threats with unmatched precision.
- Real-world US market penetration across patient segments by provider specialty
- Unmet medical need identification for pipeline development
- Comparative effectiveness positioning vs. competitors
- Discontinuation triggers and predictive modeling opportunities
FOR NEW MARKET ENTRANTS:
De-risk your launch strategy and accelerate market penetration by identifying unmet needs.
- Provider decision drivers for GLP-1 initiation, attempts, and changes
- Post-market surveillance capabilities for FDA requirements
- Health economics outcomes research for payer negotiations
- Medical affairs evidence generation for KOL engagement
FOR PIPELINE ASSETS:
Optimize clinical development and navigate regulatory pathways with robust real-world intelligence.
- Patient phenotyping for optimal clinical trial design
- Biomarker discovery opportunities in real-world populations
- Combination therapy optimization insights
Overweight and Obese Patients [BMI ≥27]
0
M
Uninterrupted Patient Journeys
0
+ Yrs
Encounters with AI-ReadyClinical Notes
0
M
EHR Source-Verified, Not Claims
0
%
A New Standard in RWE Quality ... Delivered to Your GLP-1 Evidence Platform
Gain unparalleled market intelligence and a deeper understanding of patient and provider behavior across the US obesity market.